|
|
|
|
|
|
Upcoming Highlights from the European Association of Urology 2022 Annual Meeting |
|
|
|
|
|
|
| Perioperative Treatment of Urothelial Cancer in 2022
|
| 02:15-04:30 ET | 08:15 - 10:30 CEST |
|
|
|
|
|
State-Of-The-Art Lecture: Landscape of Current Trials with Intravesical Treatment in High Risk BCG Naïve NMIBC
Presented By: Ashish Kamat, MD, MBBS
|
|
|
|
|
|
| Controversies in Onco-Urology
|
| 04:30-08:35 ET | 10:30 - 14:35 CEST |
|
|
|
|
|
How Should PET-Detected Oligorecurrent Prostate Cancer Best Treated? Systemic therapy
Presented By: Christopher Sweeney, MBBS
|
|
|
|
|
|
How Should PET-Detected Oligorecurrent Prostate Cancer Best Treated? Metastasis-Directed Therapy
Presented By: Alberto Briganti, MD, PhD
|
|
|
|
|
|
| New Insights in the Management of Upper Tract Urothelial Cancer
|
| 06:30-08:00 ET | 12:30-14:00 CEST
|
|
|
|
|
|
A0292: Elevated Hemoglobin: Creatinine Ratio Is a Novel Preoperative Marker for Worsened Survival Outcomes in Upper Tract Urothelial Carcinoma: Analysis from the Robuust Registry
Presented By: Ithaar Derweesh, MD
|
|
|
|
|
|
A0305: Implementing the Follow-up Schedule After Radical Nephrouretrectomy for Low Risk Upper Tract Urothelial Carcinoma
Presented By: Alberto Martini, MD
|
|
|
|
|
|
| Joint Session of the EAU, EANM, ESMO and ESTRO: Modern Diagnostic and Therapeutic Approaches in PCa
|
| 08:00-09:30 ET | 14:00 - 15:30 CEST
|
|
|
|
|
|
Recurring Disease: PSMA in Staging for Recurring Prostate Cancer
Presented By: Stefano Fanti, MD
Recurring Disease: Salvage Treatment Options for the PSMA Avid Lesion: Radiotherapy
Presented By: Gert De Meerleer, MD, Ph.D.
Metastatic Disease: Possible Synergies Between Radioligand and Systemic Treatment in M1 Prostate Cancer? Future Perspectives
Presented By: Ken Herrmann, MD, MBA
|
|
|
|
|
|
|
|
|
|
|
| 8th ESO Prostate Cancer Observatory: Innovations and Care in the Next 12 Months
|
| 09:45-11:45 ET | 15:45 - 17:45 CEST |
|
|
|
|
|
The Imaging Specialist's Perspective on PSMA-PET/CT
Presented By: Stefano Fanti, MD
|
|
|
|
|
|
|
|
| Management of mHSPC
|
| 04:30-06:00 ET | 10:30 - 12:00 CEST |
|
|
|
|
|
State of the Art Lecture: PSMA-PET/CT for Staging and Monitoring of Advanced Prostate Cancer
Presented By: Tarik Esen, MD
State of the Art Lecture: Synchronous vs Metachronous mHSPC: What Makes the Difference?
Presented By: Christopher Sweeney, MBBS
State of the Art Lecture: Future Perspectives in the Management of mHSPC: Where Are We Heading To? Presented By: E.J.K. Axcrona
|
|
|
|
|
|
|
|
|
|
|
| Improvements in Metastatic Prostate Cancer: Focus on Imaging and Treatment
|
| 06:15-07:45 ET | 12:15 - 13:45 CEST |
|
|
|
|
|
A0514: Sustained Castration to < 20 Ng/dl for Relugolix vs. Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Presented By: Bertrand Tombal,MD, Ph.D.
|
|
|
|
|
|
A0520: Major Adverse Cardiovascular Event Risk Following Androgen Deprivation Therapy
Presented By: E. David Crawford, MD
|
|
|
|
|
|
|
|
| Game Changing Session 5
|
| 01:30-02:00 ET | 07:30 - 08:00 CEST |
|
|
|
|
|
Exploratory Endpoints from PROpel: A Phase III Trial of Abiraterone + Olaparib Versus Abiraterone + Placebo in 1st Line mCRPC
Presented By: Noel Clarke, MBBS, FRCS, ChM
|
|
|
|
|
|
| Game Changing Session 6
|
| 01:30-02:00 ET | 07:30 - 08:00 CEST |
|
|
|
|
|
Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel by Stratification Factors in the Phase 3 ARASENS Trial
Presented By: Bertrand Tombal,MD, Ph.D.
|
|
|
|
|
|
| All You Need to Know About CRPC
|
| 08:00-09:30 ET | 14:00 - 15:30 CEST |
|
|
|
|
|
PSMA Theranostics in the mCRPC Space
Presented By: Simon Chowdhury, MD
|
|
|
|
|
|
Innovative Future Treatment Options for mCRPC
Presented By: Alicia Morgans, MD, MPH
|
|
|
|
|
|
|
